Aicella develops AI-driven tools for CAR-T therapy process optimization, utilizing a data dashboard that correlates critical process parameters with patient responses. This approach addresses inefficiencies in cell therapy R&D, ensuring compliance with Good Manufacturing Practices and facilitating smoother transitions from research to clinical applications.
Funding
$170K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
CAR-T cell therapy development faces challenges in identifying critical process parameters that reliably predict patient responses, leading to inefficiencies in R&D and hindering the transition from research to clinical applications while maintaining Good Manufacturing Practices (GMP). Traditional methods often lack the ability to uncover complex relationships between process parameters and patient outcomes.
Solution
Aicella provides an AI-driven data dashboard, Aicella InsightsTM, that correlates critical process parameters with patient responses to optimize CAR-T cell therapy development. The platform leverages machine learning and deep learning algorithms to analyze real-world data, providing insights into process parameters that dictate treatment success. Aicella's comprehensive offering includes GMP-oriented process development, verification of AI-generated process models in their own lab, and standard operating procedures (SOPs) with recommended best practices. They also offer tech transfer assistance to Contract Development and Manufacturing Organizations (CDMOs) and support Investigational New Drug (IND) application filings.
Target Audience
Aicella's primary customers are pharmaceutical companies, biotech firms, research institutions, and academic centers engaged in CAR-T therapy development.
Features
- Interactive AI/ML data dashboard summarizing critical process parameters correlated with patient responses
- GMP-oriented process development to facilitate the transition from research to clinical applications
- Verification of AI-generated process models in-house
- Generation of standard operating procedures (SOPs) with recommended best practices
- Assistance with tech transfer to CDMOs
- Support for Investigational New Drug (IND) application filings
- Intellectual property filing support based on AI-driven elucidation of process development